P016 improving tuberculosis re screening in inflammatory bowel disease patients receiving biologic therapy: a single center quality improvement initiative.

Biological agents have revolutionized the management of inflammatory bowel disease (IBD). There is a known increased risk of tuberculosis (TB) reactivation with biologic therapy (1). ACG guidelines recommend screening for active and latent TB infection (LTBI) prior to starting certain biologic agents (2). However, there are no consensus guideline on the utility of yearly screening testing in IBD patients without TB risk factors. With a number of patients now receiving the biologic therapy outside their primary care centers it has become increasingly difficult to effectively provide ongoing TB screening.

Source: Gastroenterology - January 25, 2020 Category: Gastroenterology Authors: David Drevno, Sherry Hickok, Sabina Ali Tags: Practice Management/Quality of Care/Quality Assurance Source Type: research